Absci Corporation (ABSI) fair value analysis
Nasdaq · Updated 2026-10-19
ABSI price how computed
Valuation status
No fair-value estimate yetABSI has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ABSI yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $8.25
- Sector
- Healthcare
- 12-month range
- $2.30–$11.62
- Market cap
- $1.42B
- From 52-week high
- -29.0%
- Shares outstanding
- 172M
- Rank in Healthcare by quality score
- #173 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Absci Corporation is a biotechnology company that develops antibody therapeutics and uses artificial intelligence and synthetic biology to design and optimize protein-based drugs. The company operates in the United States and serves the global pharmaceutical and biotechnology industry.
ABSI currently ranks #173 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.42B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.56M
- Net margin
- -7756.4%
- EPS (TTM)
- $-0.83
- Gross margin
- 100.0%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- -19.1%
- Shares outstanding
- 172M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $9.34
- 200-day average
- $6.16
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-12 (pre-market)
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-5.0%)
2026-03 ▲ beat (+5.0%)
2025-12 ▼ miss (-27.8%)
2025-09 ▲ beat (+4.8%)
2025-06 ▼ miss (-14.3%)
2025-03 ▲ beat (+4.5%)
2024-12 ▼ miss (-11.7%)
2024-09 ▼ miss (-26.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 1 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14.9
- Target vs last price
- +80.6%
What our data shows for ABSI
- Shares are trading in the middle of their 12-month price range of $2.30–$11.62.
- The 14-day relative strength index sits at a neutral 44.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ABSI's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ABSI conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ABSI show a shift in the 50/200-day trend state from uptrend to mixed this week. The valuation verdict remains awaiting full valuation as of the current assessment period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ABSI stock undervalued?
TickrTrends has no fair-value estimate for ABSI yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ABSI's TickrTrends verdict?
ABSI is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ABSI compare to other Healthcare stocks?
ABSI ranks #173 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ABSI overbought or oversold?
ABSI's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ABSI report earnings next?
ABSI's next earnings report is scheduled for 2026-11-12 (pre-market), per the published earnings calendar.
Does ABSI usually beat earnings estimates?
Over its last 8 reported quarters ABSI beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ABSI?
Of 11 analysts covering ABSI, 10 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $14.9 (+80.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.